Full Breakdown
Professor Richard Scolyer: Melanoma Pioneer and Glioblastoma Trailblazer
6/9/2026, 10:54:30 AM
Death and Experimental Glioblastoma Immunotherapy
Professor Richard Scolyer AO, world-leading melanoma pathologist and joint 2024 Australian of the Year, died on 9 June 2026 at 59 after a three-year battle with IDH-wildtype glioblastoma. Diagnosed in June 2023, he and Professor Georgina Long AO were the first patient to receive neoadjuvant combination immunotherapy and a personalised vaccine before tumour resection. The regimen maintained remission for 22 months before recurrence in March 2025.
Melanoma Breakthroughs and Immunotherapy Foundations
At the Melanoma Institute Australia, the University of Sydney and Royal Prince Alfred Hospital, Scolyer helped define modern melanoma diagnosis, classification and staging. In the 2000s, checkpoint-inhibitor drugs (anti-CTLA-4, anti-PD-1) created a “penicillin moment,” moving treatment from surgery alone to immune-based regimens. With Long, he led trials that cut Australian melanoma deaths from 1,600 in 2013 to ~1,300 a decade later and lifted five-year survival for stage III/IV disease to 55 %.
Timeline of Key Milestones
- 1998: Melanoma biobank (Anne Cust).
- 2000s: Checkpoint-inhibitor immunotherapy.
- 2017: Zero-death melanoma target.
- Jun 2023: Glioblastoma diagnosis.
- Late 2023: Neoadjuvant immunotherapy & vaccine.
- Feb 2025: *Nature Medicine* results.
- Mar 2025: Tumour recurrence.
Data & Statistics
Australian melanoma deaths fell from 1,600 (2013) to ~1,300 (2023). Five-year survival for stage III/IV melanoma is now 55 %. Glioblastoma 5-year survival worldwide is ~5 %; 25 % survive >1 year. Scolyer’s protocol extended his survival by 22 months.
Impact
Scolyer’s melanoma work helped lower national skin-cancer mortality and set global precision-oncology standards. His glioblastoma case gave the first human proof of immune activation in a brain-tumour microenvironment, informing the GIANT trial and spurring broader checkpoint-inhibitor research for CNS cancers.
Official Statements & Responses
Georgina Long called Scolyer “the ‘pathologists’ pathologist’” whose diagnostic skill was vital. Prime Minister Anthony Albanese called him “one of our brightest lights and one of our biggest hearts” and announced a state funeral. NSW Premier Chris Minns said his legacy gave Australians “more life, more time, more hope.” The family thanked the nation and hoped his openness would “make the road ahead easier and smoother for others.”
Conflicting Reports & Gaps
Early data showed immune activation, but experts stress that the clinical benefit of neoadjuvant immunotherapy for glioblastoma remains unproven pending larger, randomized trials.
Verbatim Quotes
- “I hope this has the power to transform how we treat all cancers, to think big and be courageous,” — Richard Scolyer, Pathologist
- “Bugger that,” — Richard Scolyer, on glioblastoma survival statistics
- “He faced his disease with optimism, with a smile, and with a deep sense of purpose,” — Chris Minns, NSW Premier
- “One patient does not make a change, we need to test this [treatment] rigorously,” — David Whiteman, QIMR-Berghofer Institute
What’s Next
The GIANT trial, led by the Peter MacCallum Cancer Centre, will test neoadjuvant immunotherapy in newly diagnosed glioblastoma patients. Ongoing translational work aims to refine vaccine design and identify response biomarkers, building on Scolyer’s proof-of-concept.
